1 / 28

Partnerships That Accelerate Innovation: 1+1=11

Partnerships That Accelerate Innovation: 1+1=11. June 12, 2013. Presentation Overview. The Issues New Opportunities for Collaboration How Massachusetts is Supporting New Opportunities for Collaboration. The Issues – A Brief Summary.

admon
Download Presentation

Partnerships That Accelerate Innovation: 1+1=11

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Partnerships That Accelerate Innovation: 1+1=11 June 12, 2013

  2. Presentation Overview • The Issues • New Opportunities for Collaboration • How Massachusetts is Supporting New Opportunities for Collaboration

  3. The Issues – A Brief Summary • Drug pipelines are running dry and many “blockbuster medicines” are about to lose patent protection • Traditional drug-development processes at big pharma are expensive and inefficient; the traditional business model at big pharma also is expensive and inefficient • Acquisition of biotech firms by big pharma is not solving the problem • Solutions to some of the most pressing problems lie at the intersection of diagnostiscs, biopharma, medical technology (devices), and computing • Collaboration is an increasingly important solution!

  4. The Issues • New Opportunities for Collaboration • How Massachusetts is Supporting New Opportunities for Collaboration

  5. Public-Private Partnerships Collaborations that are: • Focused on shared challenges that are critical for progress… • …and are increasingly difficult for a single sector to tackle, and/or finance alone… • …where solutions can benefit both the public and private sector (and the broader economy)

  6. Pre-competitive Consortia Collaborations that are: • Focused on shared challenges that are critical for progress… • …and are increasingly difficult for a single organization to tackle alone… • …but cannot be exploited as a standalone profit-making opportunity for any individual participant

  7. Models of Pre-competitive Consortia* 1. Open source initiatives 2. Industry consortia for R&D process innovation 3. Discovery-enabling consortia 4. Public-private consortia for knowledge creation 5. Prizes 6. Innovation incubators/insourcing 7. Industry complementor relationships 8. Virtual pharma companies Restricted Who Participates/Contributes Open Restricted Open Who Accesses Outputs *Altschulergray (2010)

  8. International Collaboration In mature industry sectors, innovation inevitably requires international collaboration • No country has all the expertise, tools, models, cohorts, etc. to address the increasing challenge of discovery and development • Knowledge creation is occurring all around the world and has to be rapidly disseminated • Research scientists seek expertise where they can find it – they are not “place based” No sector alone has the power to achieve these goals as well: public and private sectors also must increase their collaboration!

  9. The Issues • New Opportunities for Collaboration • How Massachusetts is Supporting New Opportunities for Collaboration

  10. Massachusetts: A Global Leader in Life Sciences The Massachusetts Life Sciences Supercluster: The world’s leading innovation pipeline: The Milken Institute’s 2010 ratings rank Massachusetts #1 for technology innovation World-class academic and medical institutions leading the way in life sciences research A talented workforce 95,000 workers in life sciences; 50% biopharma job growth in past decade All industry sectors -- biotechnology, pharmaceuticals, medical devices, diagnostics and bioinformatics Government leadership, through our state’s 10-year, $1 billion Life Sciences Initiative (enacted by the Massachusetts Legislature in June 2008)

  11. The Massachusetts Life Sciences Center: Who We Are and What We Do The Massachusetts Life Sciences Center develops and offers creative programs that fund innovation-driven economic development initiatives in the Massachusetts life sciences cluster, but also may have relevance for other “innovation” sectors. • Mission: • Serve as the “hub” of the Massachusetts life sciences Supercluster • Encourage innovation through investments in good science and good business • Strengthen and protect Massachusetts’ global leadership position in the life sciences • Accelerate the commercialization of promising treatments, therapies and cures • Create jobs and drive economic development

  12. The MLSC Invests to Close Gaps Across the Innovation Life Cycle... Discovery Delivery Development The MLSC Strategy: Reduce barriers, fill gaps and promote collaboration across the life sciences innovation process • Promote and fund convening and collaboration • Partner with and leverage private sector stakeholders • Invest in early stage companies (pipeline and external innovation) • Support workforce development and training • Build capacity, infrastructure and unique resources in Massachusetts

  13. …and Coalesce the Massachusetts Life Sciences “Cluster” into a “Ecosystem” • Life sciences innovation thrives in Massachusetts because of the great concentration of universities, research hospitals, educated workers, entrepreneurs, mature companies and a strong investment community. • In a high performing innovation clusters these components work well individually and together as an ecosystem 550 430+ Biopharma Biotech 400 Companies Companies Medtech Companies 122 122 Colleges & Colleges & Universities Universities Top 5 Top 5 NIH funded st st 1 1 NIH funded Research in in Research Educational Education Hospitals st st 1 1 Hospitals in in Level of Level of Workforce (US) workforce Venture Capital Venture Capital & SBIR funds & federal research per worker funds per worker MLSCInvestments

  14. Life Sciences Initiative Investment Tools $250 millionTax Incentive Program • 10 years • $1 billion • Investment $500 million Capital Fund $250m Investment Fund (subject to appropriation)

  15. Secretary of Housing and Economic Development Gregory Bialecki Secretary of Administration and Finance Jay Gonzalez President of the University of Massachusetts System Robert Caret, Ph.D. A CEO of a Massachusetts-based life sciences corporation Abbie Celniker, Ph.D., CEO, Eleven Biotherapeutics A researcher involved in the commercialization of biotechnology, pharmaceuticals or medical diagnostic products Lydia Villa-Komaroff, Director and CSO, Cytonome/ST A physician licensed to practice medicine in the Commonwealth and affiliated with an academic medical center Edward Benz, M.D., President & CEO, Dana-Farber Cancer Institute A person with financial expertise in the life sciences Joshua Boger, Ph.D., Founder & CEO (Retired), Vertex The MLSC Board of Directors –Public and Private Sector Stakeholders Provide Governance

  16. The MLSC Scientific Advisory Board FY ‘13 CHAIR: Harvey Lodish, Ph.D.,Whitehead Institute and Massachusetts Institute of Technology (MIT) Academia • James J. Collins, Ph.D., Boston University • John M. Collins, Ph.D., Center for Integration of Medicine & Innovative Technology (CIMIT) • Robert D’Amato, M.D., Ph.D.,Center for Macular Degeneration Research , Harvard Medical School and Boston Children’s Hospital • Rainer Fuchs, Ph.D., Harvard Medical School • Glenn R. Gaudette, Ph.D., Worcester Polytechnic Institute (WPI) • Judith Lieberman, Ph.D., Immune Disease Institute, Boston Children’s Hospital and Harvard Medical School • LitaL. Nelsen, Massachusetts Institute of Technology (MIT) • Barbara Osborne, Ph.D., UMass Amherst • Guillermo Tearney, M.D., Ph.D., Harvard Medical School, Harvard-MIT Division of Health Sciences and Technology (HST) and Massachusetts General Hospital • David Walt, Ph.D., Tufts University School of Medicine • Philip Zamore, Ph.D., UMass Medical School Venture Capital • Kevin Bitterman, Ph.D.,Polaris Venture Partners • T. (Teo) Dagi, M.D., M.B.A.,HLM Venture Partners • Jonathan Fleming, M.P.A.,Oxford Bioscience Partners • Henry Kay, Boston Harbor Angels • Carmichael Roberts, Ph.D., M.B.A., North Bridge Venture Partners • Lauren Silverman, Ph.D.,Novartis Option Fund Industry • James Barry, Ph.D., Arsenal Medical • Dalia Cohen, Ph.D.,ALN Associates • José-Carlos Gutiérrez-Ramos, Ph.D.,Pfizer • Dale Larson,Draper Laboratory • Alan Smith, Ph.D., Formerly of Genzyme, a SanofiCompany Entrepreneurs • Alison Taunton-Rigby, Ph.D.RiboNovix, Inc.

  17. Gaining Leverage: Public-Private PartnershipLife Sciences Center’s Impact: June ‘08 – May ‘13 Corporate Investors Matching Investments Attracted = $1.2 B NIH Public Dollars Invested/ Committed = $461 M 3 X multiplier Private Foundations Grants to Academic Organizations and Medical Centers Institutes Grants for “Shovel Ready” Capital Projects Other Private Investors Investments in Life Sciences Companies Academic Institutions

  18. Creating Opportunities for New Partnership Models Between Academia and Industry Objective: encourage industry and Massachusetts academic institutions to explore new models of collaboration in discovery and development. Awards are made on a competitive basis. Key evaluation criteria include: Impact of the focus area (product/technology) Novel aspects of the academic-industry collaboration Acceleration of “bench to bedside” Focus areas to date have included therapeutics, devices, materials and tools • The Center has awarded 8 grants totaling $4.76 million Industry partners provide a (minimum) 1:1 match

  19. Consortia in the Pre-Competitive Space • Massachusetts is a center of excellence in the field of biomedical neuroscience with world leaders representing all major fields of neurobiology and neurology. • The combination of basic neuroscience, translational, and clinical research distributed across more than a dozen world-renowned institutions amounts to what may be the highest density of neuroscience research in the world. • This provides a rich and fertile environment within which to advance our understanding and treatment of neurological disease. • The Massachusetts Life Sciences Neuroscience Consortium (MLSNC) is a pioneering new model that is designed to leverage this rich environment to: • Accelerate pre-clinical research available to the pharmaceutical industry • Introduce academic researchers to targeted research • Facilitate new models of industry-academic partnership

  20. MLSC Neuroscience Consortium Objective: Create a pioneering new model of collaboration designed to leverage Massachusetts’ rich neuroscience environment to: • Accelerate pre-clinical research available to the pharmaceutical industry • Introduce academic researchers to targeted research • Facilitate new models of industry-academic partnership • Massachusetts’ basic neuroscience, translational, and clinical research distributed across more than a dozen world-renowned institutions amounts to what may be the highest density of neuroscience research in the world. • Neuroscience Consortium Charter members: • Abbott • Biogen-Idec • EMD Serono • Janssen Research (Johnson and Johnson) • Merck • Pfizer • Sunovion (Dainippon Sumitomo)

  21. Consortia in the Pre-Competitive Space Why is this Consortium Different? • Proposed projects will be short-term and results-oriented. Timelines/milestones, budgets and objectives will be clearly defined by the industry sponsors • Industry sponsors will identify common standards, e.g. levels of validation necessary for a project objective to be considered “complete. • Industry sponsors will work in collaboration with PIs and their teams; sponsors also will contribute tools, data and other resources to the project teams to expedite their work • Results are shared with all participants; sponsors and PIs will have access to the use of any tools developed by each project • Industry sponsors will determine their interest in validated targets as projects are completed. Co-development among consortium members is an option.

  22. Consortia in the Pre-Competitive Space Role of the Massachusetts Life Sciences Center • The Massachusetts Life Sciences Center (MLSC) will use its convening power to reduce barriers to collaboration and to expedite access to the research community • By acting as an intermediary, the MLSC also will enable industry to provide funding ‘at arms length’, thereby removin some of the administrative complications of direct corporate sponsorship of academic lab research • The MLSC will “staff” the Consortium so that all administrative costs are subsidized by the state and sponsors’ investments will be fully directed to funding projects The Consortium received nearly 100 proposals in response to the initial solicitation and chose seven (7) projects to fund. For each project, a member(s) of the Consortium will work with the PI and his/her team.

  23. Free, password-protected, cloud-based portal -- Create your user profile at https://partnering.masslifesciences.com Open to MA-based life sciences companies and international life sciences companies Companies describe their business and qualities they are seeking in a partner Searchable database - MA companies can search MA and international companies, and international companies can search MA companies International Partnership Assistance Portal (IP-ap) • Objective: Make it easier for international and Massachusetts companies to identify and pursue potential partnerships . Massachusetts is open for collaboration: 24/7, 365 days a year!

  24. 11 International Collaborative Industry Program: Objectives and Approach Our belief: Approach: • Focus on collaborative life sciences industry projects in late R&D or development • Implement the collaboration through MLSC and Partner agencies in other countries • Execute through a competitive solicitation to select promising project(s) between MA-based and non-U.S. based companies • Funding from MLSC to MA companies • Funding from Partner agencies to the international company partners • Funding from each of the partner companies Objectives: • Promote and motivate collaboration between life sciences companies in Massachusetts and other countries • Provide joint funding to subsidize the costs and accelerate the execution of these projects

  25. International Collaborative Industry Program: Program Model Joint R&D Project Min. 100k Min.100k After a min. of $100k/project the rest is determined by the agency $ MLSC will match MA company contribution $ Partner Agency Min. 100k /project Min. 100k/project, Max. 500k

  26. International Collaborative Industry Program:Program at a Glance • Objective: Jointly invest in international and Massachusetts R&D partnerships . • Collaboration between MA life sciences company and a life sciences company from another participating geography • Late R&D stage with a goal of commercialization • Each company must have a well-defined role, set of responsibilities and work plan • The minimum grant level that Massachusetts applicants may be awarded by MLSC is $100,000 and the maximum will be $500,000 • MA company contribution must meet or exceed MLSC grant • Other agencies specify the terms of their funding to local companies and must provide minimum of $100,000 funding • Program will involve a two-phased competitive RFP • To receive funding, a final IP Agreement between the two companies must be submitted

  27. International Collaborative Industry Program (ICIP) Launch at BIO 2013 • The announcement of ICIP included high-level representatives from our partnering regions including: • Alsace Region in France • Quebec Province in Canada • Victoria State in Australia • Wallonia Region in Belgium

  28. Keeping in Touch www.masslifesciences.com • News updates • Program Information • Application portal Life Sciences Center Email List • 4,500 recipients • Weekly event listings • Sign up today!

More Related